Gaucher disease: Haematological presentations and complications

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 427-440

  Thomas, Alison S ^a   Mehta, Atul ^a   Hughes, Derralynn A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Gaucher disease; Glycosphingolipid; Myeloma; Splenomegaly; Thrombocytopenia

Indexed keywords

ANTITHROMBIN; CYTOCHROME P450 2D6; ELIGLUSTAT; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPID; IMIGLUCERASE; MIGLUSTAT; PROTEIN C; PROTHROMBIN; TALIGLUCERASE ALFA; THROMBOPLASTIN; VELAGLUCERASE ALFA;

ANEMIA; BIOLOGICAL THERAPY; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW BIOPSY; DIARRHEA; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME REPLACEMENT; EPISTAXIS; GAMMOPATHY; GAUCHER DISEASE; GBA GENE; GENOTYPE; HEMATOLOGIST; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; HUMAN; ILIOPSOAS HEMATOMA; IMMUNE DYSREGULATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFUSION RELATED REACTION; LEUKOCYTE; LIPID DEGRADATION; MACROPHAGE ACTIVATION; MENORRHAGIA; MICROENVIRONMENT; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; PARKINSON DISEASE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; QT PROLONGATION; REVIEW; SPLENECTOMY; SPLENOMEGALY; SUBSTRATE REDUCTION THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREMOR; WEIGHT REDUCTION;

GAUCHER DISEASE; GLYCOSPHINGOLIPID; MYELOMA; SPLENOMEGALY; THROMBOCYTOPENIA;

GAUCHER DISEASE; 1-DEOXYNOJIRIMYCIN; ANEMIA; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; ENZYME REPLACEMENT THERAPY; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPIDS; HEMORRHAGIC DISORDERS; HUMANS; INFLAMMATION; LEWY BODY DISEASE; LYSOSOMES; MACROPHAGE ACTIVATION; MULTIPLE MYELOMA; PARKINSON DISEASE; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; UNFOLDED PROTEIN RESPONSE;

EID: 84899475987     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12804     Document Type: Review

References (107)

1. Achord, D.T., Brot, F.E., Bell, C.E. & Sly, W.S. (1978) Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell, 15, 269-278.
2. Aerts, J.M. & Hollak, C.E. (1997) Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clinical Haematology, 10, 691-709.
3. Barak, V., Acker, M., Nisman, B., Kalickman, I., Abrahamov, A., Zimran, A. & Yatziv, S. (1999) Cytokines in Gaucher's disease. European Cytokine Network, 10, 205-210.
4. Barone, R., Giuffrida, G., Musso, R., Carpinteri, G. & Fiumara, A. (2000) Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I. Journal of Inherited Metabolic Disease, 23, 387-390.
5. Barton, N.W., Brady, R.O., Dambrosia, J.M., Di Bisceglie, A.M., Doppelt, S.H., Hill, S.C., Mankin, H.J., Murray, G.J., Parker, R.I. & Argoff, C.E. (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. New England Journal of Medicine, 324, 1464-1470.
6. Berrebi, A., Malnick, S.D., Vorst, E.J. & Stein, D. (1992) High incidence of factor XI deficiency in Gaucher's disease. American Journal of Hematology, 40, 153.
7. Beutler, E. & Kuhl, W. (1970) Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes. Lancet, 1, 612-613.
8. Beutler, E. & Saven, A. (1990) Misuse of marrow examination in the diagnosis of Gaucher disease. Blood, 76, 646-648.
9. Beutler, E., Nguyen, N.J., Henneberger, M.W., Smolec, J.M., McPherson, R.A., West, C. & Gelbart, T. (1993) Gaucher disease: gene frequencies in the Ashkenazi Jewish population. American Journal of Human Genetics, 52, 85-88.
10. Billett, H.H., Rizvi, S. & Sawitsky, A. (1996) Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. American Journal of Hematology, 51, 234-236.
11. Bohte, A.E., van Dussen, L., Akkerman, E.M., Nederveen, A.J., Sinkus, R., Jansen, P.L., Stoker, J. & Hollak, C.E. (2013) Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One, 8, e57507.
12. Boklan, B.F. & Sawitsky, A. (1976) Factor IX deficiency in Gaucher disease. An in vitro phenomenon. Archives of Internal Medicine, 136, 489-492.
13. Boven, L.A., van Meurs, M., Boot, R.G., Mehta, A., Boon, L., Aerts, J.M. & Laman, J.D. (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. American Journal of Clinical Pathology, 122, 359-369.
14. Brady, R.O., Kanfer, J.N. & Shapiro, D. (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochemical and Biophysical Research Communications, 18, 221-225.
15. Brady, R.O., Kanfer, J.N., Bradley, R.M. & Shapiro, D. (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. Journal of Clinical Investigation, 45, 1112-1115.
16. Brautbar, A., Elstein, D., Pines, G., Abrahamov, A. & Zimran, A. (2004) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells, Molecules, & Diseases, 32, 214-217.
17. Charrow, J., Esplin, J.A., Gribble, T.J., Kaplan, P., Kolodny, E.H., Pastores, G.M., Scott, C.R., Wappner, R.S., Weinreb, N.J. & Wisch, J.S. (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Archives of Internal Medicine, 158, 1754-1760.
18. Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G., Rosenbloom, B.E., Scott, C.R., Wappner, R.S., Weinreb, N.J. & Zimran, A. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine, 160, 2835-2843.
19. Cleeter, M.W., Chau, K.Y., Gluck, C., Mehta, A., Hughes, D.A., Duchen, M., Wood, N.W., Hardy, J., Mark, C.J. & Schapira, A.H. (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochemistry International, 62, 1-7.
20. Cox, T.M. & Schofield, J.P. (1997) Gaucher's disease: clinical features and natural history. Baillieres Clinical Haematology, 10, 657-689.
21. Cox, T., Lachmann, R., Hollak, C., Aerts, J., van, W.S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D. & Zimran, A. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355, 1481-1485.
22. Cox, T.M., Amato, D., Hollak, C.E., Luzy, C., Silkey, M., Giorgino, R. & Steiner, R.D. (2012) Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet Journal of Rare Diseases, 7, 102.
23. Deghady, A., Marzouk, I., El-Shayeb, A. & Wali, Y. (2006) Coagulation abnormalities in type 1 Gaucher disease in children. Pediatric Hematology and Oncology, 23, 411-417.
24. Dekker, N., van, D.L., Hollak, C.E., Overkleeft, H., Scheij, S., Ghauharali, K., van Breemen, M.J., Ferraz, M.J., Groener, J.E., Maas, M., Wijburg, F.A., Speijer, D., Tylki-Szymanska, A., Mistry, P.K., Boot, R.G. & Aerts, J.M. (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood, 118, e118-e127.
25. Elstein, D., Hollak, C., Aerts, J.M., van, W.S., Maas, M., Cox, T.M., Lachmann, R.H., Hrebicek, M., Platt, F.M., Butters, T.D., Dwek, R.A. & Zimran, A. (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. Journal of Inherited Metabolic Disease, 27, 757-766.
26. European Medicines Agency (2012) Refusal of the Marketing Authorisation for Elelyso (Taliglucerase alfa). EMA/756393/rev 3. European Medicines Agency, London, UK.
27. Fairley, C., Zimran, A., Phillips, M., Cizmarik, M., Yee, J., Weinreb, N. & Packman, S. (2008) Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. Journal of Inherited Metabolic Disease, 31, 738-744.
28. Fleming, R.E. & Bacon, B.R. (2005) Orchestration of iron homeostasis. New England Journal of Medicine, 352, 1741-1744.
29. de Fost, M., Vom Dahl, S., Weverling, G.J., Brill, N., Brett, S., Haussinger, D. & Hollak, C.E. (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells, Molecules, and Diseases, 36, 53-58.
30. de Fost, M., Out, T.A., de Wilde, F.A., Tjin, E.P., Pals, S.T., van Oers, M.H., Boot, R.G., Aerts, J.F., Maas, M., Vom Dahl, S. & Hollak, C.E. (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Annals of Hematology, 87, 439-449.
31. Franco, M., Collec, E., Connes, P., van den Akker, E., Billette de Villemeur, T, Belmatoug, N., von Lindern, M., Ameziane, N., Hermine, O., Colin, Y., Le Van Kim, C. & Mignot, C. (2013) Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood, 121, 546-555.
32. Furbish, F.S., Steer, C.J., Krett, N.L. & Barranger, J.A. (1981) Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochimica et Biophysica Acta, 673, 425-434.
33. Gaucher, P.C.E. (1882) De l'épithélioma primitif de la rate. MD Thèse, Faculté de Médicine de Paris.
34. Gillis, S., Hyam, E., Abrahamov, A., Elstein, D. & Zimran, A. (1999) Platelet function abnormalities in Gaucher disease patients. American Journal of Hematology, 61, 103-106.
35. Giona, F., Palumbo, G., Amendola, A., Santoro, C. & Mazzuconi, M.G. (2006) Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). Journal of Thrombosis and Haemostasis, 4, 1831-1833.
36. Givol, N., Goldstein, G., Peleg, O., Shenkman, B., Zimran, A., Elstein, D. & Kenet, G. (2012) Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia, 18, 117-121.
37. Gonzalez, D.E., Turkia, H.B., Lukina, E.A., Kisinovsky, I., Dridi, M.F., Elstein, D., Zahrieh, D., Crombez, E., Bhirangi, K., Barton, N.W. & Zimran, A. (2013) Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study. American Journal of Hematology, 88, 166-171.
38. Gouaze-Andersson, V., Yu, J.Y., Kreitenberg, A.J., Bielawska, A., Giuliano, A.E. & Cabot, M.C. (2007) Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochimica et Biophysica Acta, 1771, 1407-1417.
39. Grabowski, G.A. (1997) Gaucher disease: gene frequencies and genotype/phenotype correlations. Genetic Testing, 1, 5-12.
40. Grabowski, G.A. (2000) Gaucher disease: considerations in prenatal diagnosis. Prenatal Diagnosis, 20, 60-62.
41. Grabowski, G.A., Barton, N.W., Pastores, G., Dambrosia, J.M., Banerjee, T.K., McKee, M.A., Parker, C., Schiffmann, R., Hill, S.C. & Brady, R.O. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine, 122, 33-39.
42. Greenberg, A.J., Rajkumar, S.V. & Vachon, C.M. (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood, 119, 5359-5366.
43. Hill, S.C., Damaska, B.M., Ling, A., Patterson, K., Di Bisceglie, A.M., Brady, R.O. & Barton, N.W. (1992) Gaucher disease: abdominal MR imaging findings in 46 patients. Radiology, 184, 561-566.
44. Hollak, C.E., Levi, M., Berends, F., Aerts, J.M. & van Oers, M.H. (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. British Journal of Haematology, 96, 470-476.
45. Hollak, C.E., Belmatoug, N., Cole, J.A., Vom Dahl, S., Deegan, P.B., Goldblatt, J., Rosenbloom, B., van Dussen, L., Tylki-Szymańska, A., Weinreb, N.J., Zimran, A. & Cappellini, MD. (2012) Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. British Journal of Haematology, 158, 528-538.
46. Hughes, D., Cappellini, M.D., Berger, M., Van Droogenbroeck, J., de Fost, M., Janic, D., Marinakis, T., Rosenbaum, H., Villarubia, J., Zhukovskaya, E. & Hollak, C. (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. British Journal of Haematology, 138, 676-686.
47. Ida, H., Rennert, O.M., Ito, T., Maekawa, K. & Eto, Y. (1998) Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells, Molecules, & Diseases, 24, 73-81.
48. Jurecka, A., Gregorek, H., Kleinotiene, G., Czartoryska, B. & Tylki-Szymanska, A. (2011) Gaucher disease and dysgammaglobulinemia: a report of 61 patients, including 18 with GD type III. Blood Cells, Molecules, & Diseases, 46, 85-87.
49. Kanazawa, T., Nakamura, S., Momoi, M., Yamaji, T., Takematsu, H., Yano, H., Sabe, H., Yamamoto, A., Kawasaki, T. & Kozutsumi, Y. (2000) Inhibition of cytokinesis by a lipid metabolite, psychosine. Journal of Cell Biology, 149, 943-950.
50. Kattlove, H.E., Williams, J.C., Gaynor, E., Spivack, M., Bradley, R.M. & Brady, R.O. (1969) Gaucher cells in chronic myelocytic leukemia: an acquired abnormality. Blood, 33, 379-390.
51. Katz, K., Tamary, H., Lahav, J., Soudry, M. & Cohen, I.J. (1999) Increased operative bleeding during orthopaedic surgery in patients with type I Gaucher disease and bone involvement. Bulletin/Hospital for Joint Diseases, 58, 188-190.
52. Kelsey, H., Christopoulos, C., Gray, A.A. & Machin, S.J. (1994) Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease. Journal of Clinical Pathology, 47, 162-165.
53. Khan, A., Hangartner, T., Weinreb, N.J., Taylor, J.S. & Mistry, P.K. (2012) Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Journal of Bone and Mineral Research, 27, 1839-1848.
54. Koprivica, V., Stone, D.L., Park, J.L., Callahan, M., Frisch, A. & Cohen, I.J. (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. American Journal of Human Genetics, 66, 1777-1786.
55. Lachmann, R.H., Grant, I.R., Halsall, D. & Cox, T.M. (2004) Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM, 97, 199-204.
56. Lecourt, S., Mouly, E., Freida, D., Cras, A., Ceccaldi, R., Heraoui, D., Chomienne, C., Marolleau, J.P., Arnulf, B., Porcher, R., Caillaud, C., Vanneaux, V., Belmatoug, N. & Larghero, J. (2013) A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. PLoS One, 8, e69293.
57. Liu, J., Halene, S., Yang, M., Iqbal, J., Yang, R., Mehal, W.Z., Chuang, W.L., Jain, D., Yuen, T., Sun, L., Zaidi, M. & Mistry, P.K. (2012) Gaucher disease gene GBA functions in immune regulation. Proceedings of the National Academy of Sciences of the United States of America, 109, 10018-10023.
58. Lo, S.M., Stein, P., Mullaly, S., Bar, M., Jain, D., Pastores, G.M. & Mistry, P.K. (2010) Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types - correlation with genotype and phenotype. American Journal of Hematology, 85, 340-345.
59. Lukina, E., Watman, N., Arreguin, E.A., Dragosky, M., Iastrebner, M., Rosenbaum, H., Phillips, M., Pastores, G.M., Kamath, R.S., Rosenthal, D.I., Kaper, M., Singh, T., Puga, A.C. & Peterschmitt, M.J. (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood, 116, 4095-4098.
60. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E. & Sidransky, E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Molecular Genetics and Metabolism, 81, 70-73.
61. Maaswinkel-Mooij, P., Hollak, C., van Eysden-Plaisier, M., Prins, M., Aerts, H. & Poll, R. (2000) The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. Journal of Inherited Metabolic Disease, 23, 77-82.
62. Maegawa, G.H., Tropak, M.B., Buttner, J.D., Rigat, B.A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G.J., Hamuro, Y., Clarke, J.T. & Mahuran, D.J. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. Journal of Biological Chemistry, 284, 23502-23516.
63. Maor, G., Rencus-Lazar, S., Filocamo, M., Steller, H., Segal, D. & Horowitz, M. (2013) Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet Journal of Rare Diseases, 8, 140.
64. Meikle, P.J., Hopwood, J.J., Clague, A.E. & Carey, W.F. (1999) Prevalence of lysosomal storage disorders. JAMA, 281, 249-254.
65. Mellemkjoer, L., Olsen, J.H., Linet, M.S., Gridley, G. & McLaughlin, J.K. (1995) Cancer risk after splenectomy. Cancer, 75, 577-583.
66. Mistry, P.K., Sirrs, S., Chan, A., Pritzker, M.R., Duffy, T.P., Grace, M.E., Meeker, D.P. & Goldman, M.E. (2002) Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Molecular Genetics and Metabolism, 77, 91-98.
67. Mistry, P.K., Sadan, S., Yang, R., Yee, J. & Yang, M. (2007) Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. American Journal of Hematology, 82, 697-701.
68. Mistry, P.K., Deegan, P., Vellodi, A., Cole, J.A., Yeh, M. & Weinreb, N.J. (2009) Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal of Haematology, 147, 561-570.
69. Mistry, P.K., Liu, J., Yang, M., Nottoli, T., McGrath, J., Jain, D., Zhang, K., Keutzer, J., Chuang, W.L., Mehal, W.Z., Zhao, H., Lin, A., Mane, S., Liu, X., Peng, Y.Z., Li, J.H., Agrawal, M., Zhu, L.L., Blair, H.C., Robinson, L.J., Iqbal, J., Sun, L. & Zaidi, M. (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proceedings of the National Academy of Sciences of the United States of America, 107, 19473-19478.
70. Mitrovic, M., Sumarac, Z., Antic, D., Bogdanovic, A., Elezovic, I., Vukosavljevic, D., Ignjatovic, S., Majkic-Singh, N. & Suvajdzic, N. (2012) Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: effects of enzyme replacement therapy. Blood Cells, Molecules, & Diseases, 49, 58-59.
71. Morgan, M.A., Hoffbrand, A.V., Laulicht, M., Luck, W. & Knowles, S. (1983) Serum ferritin concentration in Gaucher's disease. British Medical Journal (Clinical Research Ed.), 286, 1864.
72. Neudorfer, O., Hadas-Halpern, I., Elstein, D., Abrahamov, A. & Zimran, A. (1997) Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients. American Journal of Hematology, 55, 28-34.
73. Park, S.Y., Kwak, C.Y., Shayman, J.A. & Kim, J.H. (2012) Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochimica et Biophysica Acta, 1820, 1141-1148.
74. Parkin, J.L. & Brunning, R.D. (1982) Pathology of the Gaucher cell. Progress in Clinical and Biological Research, 95, 151-175.
75. Pastores, G.M., Weinreb, N.J., Aerts, H., Andria, G., Cox, T.M., Giralt, M., Grabowski, G.A., Mistry, P.K. & Tylki-Szymanska, A. (2004) Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology, 41, 4-14.
76. Pavlova, E.V., Wang, S.Z., Archer, J., Dekker, N., Aerts, J.M., Karlsson, S. & Cox, T.M. (2013) B cell lymphoma and myeloma in murine Gaucher's disease. Journal of Pathology, 231, 88-97.
77. Pelled, D., Trajkovic-Bodennec, S., Lloyd-Evans, E., Sidransky, E., Schiffmann, R. & Futerman, A.H. (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiology of Disease, 18, 83-88.
78. Platt, F.M., Neises, G.R., Dwek, R.A. & Butters, T.D. (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Journal of Biological Chemistry, 269, 8362-8365.
79. Pratt, P.W., Kochwa, S. & Estren, S. (1968) Immunoglobulin abnormalities in Gaucher's disease. Report of 16 cases. Blood, 31, 633-640.
80. Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J.L., Bataille, R. & Amiot, M. (1999) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. British Journal of Haematology, 107, 392-395.
81. Radin, N.S. (1982) Inhibitors and stimulators of glucocerebroside metabolism. Progress in Clinical and Biological Research, 95, 357-383.
82. Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Melton, L.J. III, Bradwell, A.R., Clark, R.J., Larson, D.R., Plevak, M.F., Dispenzieri, A. & Katzmann, J.A. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 106, 812-817.
83. Ringden, O., Groth, C.G., Erikson, A., Backman, L., Granqvist, S., Mansson, J.E. & Svennerholm, L. (1988) Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. Transplantation, 46, 66-70.
84. Rodic, P., Pavlovic, S., Kostic, T., Suvajdzic, V.N., Djordjevic, M., Sumarac, Z., Dajak, M., Bonaci, N.B. & Janic, D. (2013) Gammopathy and B lymphocyte clonality in patients with Gaucher type I disease. Blood Cells, Molecules, & Diseases, 50, 222-225.
85. Ron, I., Rapaport, D. & Horowitz, M. (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Human Molecular Genetics, 19, 3771-3781.
86. Rosenbloom, B.E., Weinreb, N.J., Zimran, A., Kacena, K.A., Charrow, J. & Ward, E. (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood, 105, 4569-4572.
87. Rosenbloom, B.E., Becker, P. & Weinreb, N. (2009) Multiple myeloma and Gaucher genes. Genetics in Medicine, 11, 134.
88. Salky, B., Kreel, I., Gelernt, I., Bauer, J. & Aufses, A.H. Jr (1979) Splenectomy for Gaucher's disease. Annals of Surgery, 190, 592-594.
89. Shayman, J.A. (2013) Eliglustat tartrate, a prototypic glucosylceramide synthase inhibitor. Expert Review of Endocrinology & Metabolism, 8, 491-504.
90. Shiran, A., Brenner, B., Laor, A. & Tatarsky, I. (1993) Increased risk of cancer in patients with Gaucher disease. Cancer, 72, 219-224.
91. Shoenfeld, Y., Gallant, L.A., Shaklai, M., Livni, E., Djaldetti, M. & Pinkhas, J. (1982) Gaucher's disease: a disease with chronic stimulation of the immune system. Archives of Pathology and Laboratory Medicine, 106, 388-391.
92. Sidransky, E. (2004) Gaucher disease: complexity in a "simple" disorder. Molecular Genetics and Metabolism, 83, 6-15.
93. Spectre, G., Roth, B., Ronen, G., Rosengarten, D., Elstein, D., Zimran, A., Varon, D. & Revel-Vilk, S. (2011) Platelet adhesion defect in type I Gaucher disease is associated with a risk of mucosal bleeding. British Journal of Haematology, 153, 372-378.
94. Steet, R.A., Chung, S., Wustman, B., Powe, A., Do, H. & Kornfeld, S.A. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 103, 13813-13818.
95. Stein, P., Malhotra, A., Haims, A., Pastores, G.M. & Mistry, P.K. (2010a) Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. Journal of Inherited Metabolic Disease, 33, 769-774.
96. Stein, P., Yu, H., Jain, D. & Mistry, P.K. (2010b) Hyperferritinemia and iron overload in type 1 Gaucher disease. American Journal of Hematology, 85, 472-476.
97. Sun, Y. & Grabowski, G.A. (2010) Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy, 6, 648-649.
98. Taddei, T.H., Kacena, K.A., Yang, M., Yang, R., Malhotra, A., Boxer, M., Aleck, K.A., Rennert, G., Pastores, G.M. & Mistry, P.K. (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal of Hematology, 84, 208-214.
99. Thomas, A.S., Mehta, A.B. & Hughes, D.A. (2013) Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells, Molecules, & Diseases, 50, 212-217.
100. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712-3720.
101. Weinreb, N.J., Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G., Rosenbloom, B.E., Scott, C.R., Wappner, R.S. & Zimran, A. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine, 113, 112-119.
102. Zimran, A., Kay, A., Gelbart, T., Garver, P., Thurston, D., Saven, A. & Beutler, E. (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore), 71, 337-353.
103. Zimran, A., Altarescu, G., Rudensky, B., Abrahamov, A. & Elstein, D. (2005a) Survey of hematological aspects of Gaucher disease. Hematology, 10, 151-156.
104. Zimran, A., Liphshitz, I., Barchana, M., Abrahamov, A. & Elstein, D. (2005b) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells, Molecules, & Diseases, 34, 197-200.
105. Zimran, A., Altarescu, G., Philips, M., Attias, D., Jmoudiak, M., Deeb, M., Wang, N., Bhirangi, K., Cohn, G.M. & Elstein, D. (2010) Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood, 115, 4651-4656.
106. Zimran, A., Brill-Almon, E., Chertkoff, R., Petakov, M., Blanco-Favela, F., Munoz, E.T., Solorio-Meza, S.E., Amato, D., Duran, G., Giona, F., Heitner, R., Rosenbaum, H., Giraldo, P., Mehta, A., Park, G., Phillips, M., Elstein, D., Altarescu, G., Szleifer, M., Hashmueli, S. & Aviezer, D. (2011) Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood, 118, 5767-5773.
107. Zimran, A., Altarescu, G. & Elstein, D. (2013) Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells, Molecules, & Diseases, 50, 134-137.